Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause

Citation
N. Mendoza et al., Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause, MATURITAS, 37(1), 2000, pp. 37-43
Citations number
20
Categorie Soggetti
Reproductive Medicine","Medical Research General Topics
Journal title
MATURITAS
ISSN journal
03785122 → ACNP
Volume
37
Issue
1
Year of publication
2000
Pages
37 - 43
Database
ISI
SICI code
0378-5122(20001130)37:1<37:LEEAAO>2.0.ZU;2-N
Abstract
Objective: To compare the effectiveness of tibolone and 17 beta -estradiol on climacteric symptoms, lipid and biochemical parameters in women with sur gical menopause, Methods: In a prospective randomised clinical trial group comparative study, the effects on the aforementioned parameters, as well as treatment compliance and side effects were studied with oral tibolone 2.5 mg per day and with transdermic 17 beta -estradiol at 50 mug per day for a period of 12 months. Statistical analysis was carried out using the Fisher- test, analysis of the variance (ANOVA) for the two factors and the Bouferon i test. Results: Lipid metabolism analysis showed lower levels of HDL and t riglycerides in the tibolone group. Other biochemical parameters were not a ffected. Similar reductions in climacteric symptoms were found in both the groups, but the tibolone group revealed a greater improvement in psychologi cal problems and in sexual behaviour. No differences were observed with res pect to compliance and side effects. Conclusions: Tibolone is as effective or more than 17 beta -estradiol in reducing climacteric symptoms, and shows greater triglyceride and total cholesterol improvements. Tibolone is a goo d alternative to estrogens in women with surgical menopause. (C) 2000 Elsev ier Science Ireland Ltd. All rights reserved.